Montanova Capital LLC Increases Stake in Zura Bio Limited $ZURA

Montanova Capital LLC lifted its position in Zura Bio Limited (NASDAQ:ZURA) by 4.1% in the 2nd quarter, Holdings Channel.com reports. The fund owned 9,443,001 shares of the company’s stock after acquiring an additional 376,000 shares during the period. Zura Bio comprises 0.9% of Montanova Capital LLC’s investment portfolio, making the stock its 28th largest holding. Montanova Capital LLC owned approximately 0.10% of Zura Bio worth $55,714,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Commodore Capital LP purchased a new stake in Zura Bio in the 1st quarter worth about $19,338,000. Siren L.L.C. boosted its position in shares of Zura Bio by 187.3% during the first quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock valued at $22,222,000 after buying an additional 2,434,866 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Zura Bio by 78.7% during the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after buying an additional 2,052,732 shares during the period. EcoR1 Capital LLC bought a new position in shares of Zura Bio during the first quarter valued at approximately $7,019,000. Finally, Stempoint Capital LP bought a new position in shares of Zura Bio during the first quarter valued at approximately $4,483,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZURA has been the subject of a number of research analyst reports. Wall Street Zen raised Zura Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. William Blair began coverage on Zura Bio in a research note on Wednesday, July 8th. They issued an “outperform” rating on the stock. Wedbush lifted their target price on Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Guggenheim boosted their target price on shares of Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Zura Bio Stock Performance

Zura Bio stock opened at $5.54 on Tuesday. The company has a 50 day moving average price of $5.47 and a 200-day moving average price of $5.38. Zura Bio Limited has a fifty-two week low of $1.88 and a fifty-two week high of $7.44. The company has a market capitalization of $530.90 million, a PE ratio of -4.90 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, analysts forecast that Zura Bio Limited will post -0.81 earnings per share for the current year.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.